Chemical Structure (Alogliptin 01)
Alogliptin Tablet, Film Coated
Product Images NDC 50090-5574
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Alogliptin (NDC 50090-5574). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 (Alogliptin 02)
This text appears to be a list of different dosages and administration recommendations for the medication Alogliptin, as well as interactions with other drugs. Alogliptin is a substrate for several enzymes, including CYP1A2, CYP2C8, CYP2CS, CYP2D6, CYP3A4, and Pgp. The text also includes information on the renal excretion of Alogliptin and recommendations for coadministration with other drugs such as Metformin, Cimetidine, Pioglitazone, Warfarin, Glyburide, Tolbutamide, Dextromethorphan, Atorvastatin, Ethinyl Estradiol, Norethindrone, Midazolam, Digoxin, and Fexofenadine. There is no information provided on the purpose or use of Alogliptin itself.*
Figure 2 (Alogliptin 03)
This appears to be a list of medications and their dosages in relation to their effect on various enzymes in the body. The list includes information on drugs that either inhibit or are substrates of certain enzymes with recommended dosage adjustments or no adjustments needed. One of the medications, Alogliptin, is mentioned multiple times with various doses and single-dose options, but a clear recommendation for dosage adjustment is not given.*
Figure 3 (Alogliptin 04)
This is a table or chart displaying different mean A1C values and changes in A1C for a study comparing the effectiveness of a placebo, Alogliptin, Pioglitazone, and a combination of Alogliptin and Pioglitazone. The study was conducted on an intent-to-treat population using the last observation on the study, and the results are compared using p-values.*
Figure 4 (Alogliptin 05)
The text appears to be a section of a medical study report, comparing the effectiveness of NESINA and Placebo medication for a certain condition. The report mentions the comparison between NESINA and Placebo regarding HR (heart rate) and provides some statistical figures in table form, indicating the number of people at risk and the duration of the treatment.*
Label Image (Lbl500905574)
This description provides information about a product T BHA-O labeled as "hCocLeTin 25 MG." It appears to contain 30 tablets and requires storage at a certain temperature ("SToRE AT 7 REES £"). However, the initial text "1mc, zotpe" is not clear and might not be relevant to the product description.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
